Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma von Monge B., M. Cecilia, Coffman, Kelley Lauren, Hrones, Donna M., Steinberg, Seth M., Redd, Bernadette, Wood, Bradford, Xie, Changqing, Greten, Tim F.

Volltext

A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC) von Xie, Changqing, Monge B., M. Cecilia, Mabry-Hrones, Donna, Coffman, Kelley Lauren, Hicks, Stephanie, Redd, Bernadette, Wood, Brad, Highfill, Steven, Ho, Mitchell, Greten, Tim F.

Volltext

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers von Coffman, Kelley Lauren, Xie, Changqing, Hrones, Donna M., Monge B., M. Cecilia, Kleiner, David E., Steinberg, Seth M., Redd, Bernadette, Wood, Brad J., Kassin, Michael, Levy, Elliot, Benmebarek, Mohamed-Reda, Greten, Tim F.

Volltext

Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE von Coffman, Kelley Lauren, Bodei, Lisa, Le, Tiffany, Choi, Ye, Chou, Joanne F., Capanu, Marinela, Dunphy, Mark, Fox, Josef J., Grewal, Ravinder K, Reddy, Ryan, Riedl, Christopher, Schöder, Heiko, Reidy, Diane Lauren, Raj, Nitya Prabhakar

Volltext